

Leucine-Rich Repeat Kinase 2 and Alternative Splicing in Parkinson's disease

Author:

Elliott, David A; Woojin, Scott Kim; Gorissen, Sarsha; Halliday, Glenda; Kwok, John BJ

Publication details:

Movement Disorders

v. 27

Chapter No. 8

pp. 1004-1011

0885-3185 (ISSN)

Publication Date:

2012

Publisher DOI:

<http://dx.doi.org/10.1002/mds.25005>

License:

<https://creativecommons.org/licenses/by-nc-nd/3.0/au/>

Link to license to see what you are allowed to do with this resource.

Downloaded from <http://hdl.handle.net/1959.4/53341> in <https://unsworks.unsw.edu.au> on 2024-04-19

Leucine-Rich Repeat Kinase 2 and Alternative Splicing in Parkinson's disease

David A Elliott, PhD ^{1,2}, Woojin Scott Kim, PhD ^{1,2}, Sarsha Gorissen, BSc ¹, Glenda M Halliday, PhD ^{1,2}, John B J Kwok, PhD ^{1,2}.

1. Neuroscience Research Australia, Sydney, NSW, Australia
2. School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia

Corresponding author:

Dr John BJ Kwok

Neuroscience Research Australia

Barker St, Randwick, Sydney, NSW, 2031

Australia

Phone +61 2 9399 1025

Fax +61 2 9399 1005

E-mail: j.kwok@neura.edu.au

Number of:

References 33

Figures 4

Table 1

Word Count of:

Title 76 characters

Introductory Paragraph 250 words (limit 250 words)

Key words: Parkinson's disease; Leucine-rich repeat kinase 2; microarray; alternative splicing; dystonin; alpha-synuclein; microtubule-associated protein tau

Abbreviations: *ASPM*, asp (abnormal spindle)-like, microcephaly gene; *BRCA1*, breast cancer 1 gene; cDNA, complementary DNA; *CD1C*, CD1C antigen precursor gene; *CHORDC1*, cysteine and histidine-rich domain-containing gene; *CHMP2B*, chromatin modifying protein 2B gene; *CNIH4*, cornichon homolog 4 gene; *DICER1*, dicer 1 gene; *DPY19L4*, dpy-19-like 4 gene; *DST*, Dystonin gene; *FAM188A*, Homo sapiens family with sequence similarity 188, member A gene, FDR, false discovery rate; *FUS*, fused in sarcoma gene; *HSP5*, Hermansky-Pudlak syndrome 5 gene; *LRRK2*, leucine-rich repeat kinase 2 gene; *MAPK8*, mitogen-activated protein kinase 8 isoform gene; *MAPT*, microtubule-associated protein tau gene; *MPHOSPH10*, M-phase phosphoprotein 10 gene; *NLG1*, neuroligin 1 gene; *NDUFA4*, NADH dehydrogenase (ubiquinone) 1 alpha gene; *PPM1A*, protein phosphatase 1A gene; *PRKaR2B*, cAMP-dependent protein kinase, regulatory gene; *RAB1A*, member RAS oncogene family isoform 1 gene; RT-PCR, reverse transcription-polymerase chain reaction; *SMAD2*, Sma- and Mad-related protein 2 gene; *SNCA*, alpha-synuclein gene; *TARDBP*, TAR DNA binding protein gene; *TMEM100*, transmembrane protein 100 gene; *VANG1*, vang-like 1 gene; *ZNRD1*, zinc ribbon domain containing 1 gene.

ABSTRACT

Background: Mutations of the leucine rich repeat kinase 2 (*LRRK2*) gene are the most common genetic cause of Parkinson's disease (PD) and are associated with pleiomorphic neuropathology. We hypothesise that *LRRK2* mediates its pathogenic effect via alternative splicing of neurodegeneration genes.

Methods: Western blot analysis of subcellular protein fractions. Exon-array analysis of RNA from cultured neuroblastoma cells transfected with *LRRK2* expression vectors. Reverse-transcription PCR (RT-PCR) of RNA from cultured cells and post-mortem tissue.

Results: Over-expression of *LRRK2* G2019S mutant resulted in a significant 2.6 fold ($p = 0.020$) decrease in nuclear TDP-43 levels. Exon-array analyses revealed that wildtype *LRRK2* had a significant effect on expression of genes with nuclear ($p < 10^{-22}$) and cell cycle functions ($p < 10^{-15}$). We replicated changes in gene expression in 30% of selected genes by quantitative RT-PCR. Over-expression of *LRRK2* resulted in altered splicing of two genes associated with PD, with an increased inclusion of exon 10 of *MAPT* (1.7 fold; $p = 0.001$) and exon 5 of the *SNCA* gene (1.6 fold; $p = 0.005$). Moreover, over-expression of *LRRK2* (G2019S), *TARDBP* (M337V) and *FUS* (R521H) mutants was associated with decreased inclusion out of the *DST* 1e precursor exons in SK-N-MC cells. Altered splicing of *SNCA* (1.9 fold; $p < 0.001$) and *DST* genes (log2 2.3 fold; $p = 0.005$) was observed in a cohort of PD compared with neurologically normal brains.

Conclusions: Our study highlights the importance of aberrant RNA metabolism as a common pathogenic pathway for idiopathic PD, mediated in part by *LRRK2* dysfunction.

INTRODUCTION

Parkinson's disease (PD, OMIM 168600) is the second most common progressive neurodegenerative disorder, affecting approximately 2% of the population at 65 years of age.¹ The disease is characterised clinically by a combination of motor symptoms including tremor, bradykinesia and rigidity.¹ Neuropathologically, the disease is characterised by severe loss of dopaminergic neurons in the substantia nigra and cytoplasmic inclusions comprised mainly of α -synuclein, known as Lewy bodies.² The leucine rich repeat kinase (*LRRK2*) gene codes for a large 2527 amino acid, GTPase/kinase protein³ that has multiple physiological roles.⁴⁻⁶ *LRRK2* mutations cause ~7% of familial PD cases⁷ and the most common mutation is a glycine for serine amino acid substitution at codon position 2019 (G2019S).⁸ While most patients with *LRRK2* mutations have typical Lewy body pathology, some cases have substantia nigra degeneration alone (one with TAR DNA binding protein 43 (TDP-43) immunopositive inclusions), while others have tau immunopositive inclusions consistent with frontotemporal lobar degenerations (FTLD).⁹ These observations suggest that *LRRK2* serves as an upstream central integrator of multiple cell signalling pathways.¹⁰

A significant proportion of the human genome is alternatively spliced, a process that allows individual genes to express multiple protein isoforms with diverse functions.¹¹ There is evidence that the neurodegenerative process involves the disruption of mechanisms regulating mRNA metabolism and alternative splicing. Firstly, mutations have been identified in the TDP-43 (*TARDBP*) and fused in sarcoma (*FUS*) genes in familial forms of motor neuron disease.¹² These genes code for heterogeneous nuclear ribonucleoprotein (hnRNP) implicated in exon splicing and transcription regulation.¹⁹ Moreover, a link between environmental insults and alternative splicing has been identified. The treatment of neuronal cells with paraquat, a pesticide to generate models of PD, has been shown to decrease exon inclusion of a number of genes.¹³ Whilst many gene-array studies on the pathogenic role of *LRRK2* have focused on changes in overall gene expression, we

present data from exon-array analysis from cells over-expressing LRRK2 wildtype or G2019S mutant protein that demonstrate the effects of *LRRK2* on alternative splicing, and the association of the G2019S mutation with altered splicing of key neurodegenerative genes.

Materials and Methods

Expression constructs

Expression constructs with wildtype and G2019S mutant *LRRK2* complementary DNAs (cDNAs), the *TARDPB* (M337V) cDNA and *FUS* (R521H) cDNA were made as previously reported.¹⁴⁻¹⁶

Determination of TDP-43 levels and Subcellular Localisation

Subcellular levels of TDP-43 protein were determined by Western blotting as previously reported.¹⁷

Lipid raft assay

Lipid raft and non-raft fractions were prepared from cells according to their solubility in detergent as described previously.¹⁸

Exon-array analyses

Recombinant vectors were transfected into the human neuroblastoma line, SK-N-MC, and left for 48 hours prior to total RNA extraction. Microarray analysis using the human GeneChip® Exon 1.0 ST Arrays (Affymetrix) was performed by the Ramaciotti Centre for Gene Function Analyses (University of New South Wales, Australia).

SYBR semi-quantitative realtime RT-PCR validation of gene expression

PCR Primers for the validation of each candidate gene were designed to span exon/exon boundaries to minimise the effects of genomic DNA contamination. The complete set of primers is listed in Supplementary Table 1.

RT-PCR validation of alternative splicing

PCR primers for each candidate gene were designed to flank the alternatively spliced exon. The complete set of primers is listed in Supplementary Table 2.

PD and neuropathologically normal control autopsy cases for comparison

Brain tissue from 10 non-demented PD cases (7 males, 3 females, age = 79 ± 2.7 years, postmortem delay 9 ± 2.9 hours) and 8 controls (4 males, 4 females, age = 86 ± 1.4 years, postmortem delay 11 ± 1.8 hours) was obtained with approval from the Sydney Brain Bank and New South Wales Tissue Resource Centre, part of the Australian Brain Bank Network of the National Health and Medical Research Council.

Statistics

Mean differences in quantitative measures were compared with the use of two-tailed Student's *t* test. Differences in proportions were determined by Chi-square statistics. P values from validation experiments were corrected using the false discovery rate algorithm.¹⁹ Mean and standard error of the mean are given for all variables. Regression analyses were used to examine the relationship between alternative splicing levels, sex, age and post-mortem delay.

RESULTS

Over-expression of wildtype and mutant LRRK2 affect subcellular levels of TDP-43

A feature of the neuropathology associated with several LRRK2 mutations is cytoplasmic TDP-43 immunopositive inclusions.⁹ This led us to examine whether LRRK2 has a role in regulating the subcellular localization of TDP-43. Transfection of *LRRK2* cDNA expression constructs resulted in over-expression of the LRRK2 protein by approximately 12 fold (as determined by realtime RT-PCR) in transfected SK-N-MC cells relative to cells transfected with the LacZ construct (data not shown). Cells transfected with *LRRK2* G2019S mutant constructs resulted in a significant 2.6 fold

($p = 0.020$) decrease in nuclear TDP-43 levels compared with LacZ transfected cells (FIG. 1A and B). However, no significant changes were observed for TDP-43 in the cytoplasmic fractions (FIG. 1A and B). Cells transfected with wildtype *LRRK2* construct did not result in significant changes of TDP-43 in the cytoplasmic or nuclear fractions (FIG. 1A and B) relative to the LacZ control.

The LRRK2 protein has been previously shown to localise to lipid rafts, which are glycolipoprotein microdomains within cellular membranes and are thought to mediate a number of processes including protein trafficking.⁵ We examined whether the wildtype and G2019S mutant LRRK2 proteins co-localise to lipid rafts by western blotting following extraction of lipid raft and non-raft components (Supplementary materials and methods, FIG. 1C). We confirmed that both wildtype and mutant proteins localize mainly to the lipid raft fractions as previously reported.⁵ However, we did not observe any difference in the ability of the G2019S mutant to alter its affinity with lipid rafts after we normalized protein levels using the G α i-2 lipid raft specific marker and the calnexin lipid non-raft specific marker¹⁸ (FIG. 1C), suggesting that the alterations in nuclear TDP-43 levels were not mediated via a change in lipid raft localization of the mutant protein.

Over-expression of wildtype and mutant LRRK2 resulted in significant overlap in number of differentially expressed genes

We compiled a list of genes that are differentially regulated by over-expression of either wildtype or G2019S mutant *LRRK2* cDNAs compared with LacZ control (Supplementary materials and methods, Supplementary Data 1). We observed that over-expression of the wildtype *LRRK2* affected the regulation of 20 fold more genes than mutant LRRK2, despite similar levels of transgene expression. Biological pathway analyses²⁸ showed that the wildtype *LRRK2* gene list showed a significant enrichment of genes encoding nuclear proteins ($p < 2 \times 10^{-22}$) and genes involved in cell cycle ($p < 6 \times 10^{-16}$) and cell division ($p < 2 \times 10^{-15}$). Conversely, no significant enrichment of any biological pathways was observed for the *LRRK2* mutant gene list. We chose 9

target genes for validation by realtime RT-PCR (Table 1). These were genes that were specific to the wildtype *LRRK2* gene list (*CHORDC1*, *CHMP2B*, *TARDBP*, *BRCA1*, *MAPK8*, *DICER1* and *TMEM100*), genes known to be involved in neurodegeneration (*TARDBP*²² and *CHMP2B*³¹), and two genes whose expression were discordantly regulated by the wildtype and mutant *LRRK2* (*NDUFA4* and *CDIC*). We were able to significantly replicate 3 genes (*TARDBP*, transmembrane protein 100 (*TMEM100*), and *DICER1*) in which the changes in direction of gene expression were also consistent with the microarray data (Table 1). Of interest, we were able to validate a significant effect of wildtype *LRRK2* (log2 3.2 fold, $p = 0.005$) on the expression of *DICER1*, a key regulator of microRNA biogenesis.³²

Over-expression of mutant LRRK2 is associated with altered splicing of two major PD genes

We also compiled a list of genes whose exons were differentially spliced by the over-expression of wildtype or mutant *LRRK2* (Supplementary materials and methods, Supplementary Data 2) cDNAs. We observed that wildtype *LRRK2* over-expression resulted in a 2-fold increase in the number of differentially spliced genes compared with the mutant protein. Moreover, there was a significant increase in the proportion of genes that were differently spliced versus those that were differentially expressed in cells transfected with the G2019S mutant (760: 80) compared with wildtype *LRRK2* (1678: 1678) (Pearson's Chi square = 452, $p < 0.0001$) (FIG. 2A). Biological pathway analyses did not reveal any significant enrichment for the wildtype or mutant *LRRK2* gene lists. Two genes were chosen from the exon list for validation with an emphasis placed on a top hit (*CNIH4*) and gene involved in the regulation of cell death (*FAM188A*).²³ Genes were validated by RT-PCR followed by gel electrophoresis to visualize products corresponding to the inclusion or exclusion of the candidate exon. This allows us to measure both splice isoforms from each sample as a single reaction and to normalise for differences in sample concentration. Cells transfected with *LRRK2* G2019S mutant cDNA resulted in a significant 1.3 fold ($p = 0.007$) increase in inclusion of exon 3

of the cornichon homolog 4 (*CNIH4*) gene (FIG.2B and C). No significant effects were observed for the wildtype *LRRK2* cDNA (FIG.2B and C) or *FAM188A* gene (data not shown).

We then proceeded to examine previously validated alternatively spliced exons from two major PD genes, the microtubule-associated protein tau (*MAPT*) and alpha-synuclein (*SNCA*) genes.²⁴ Similar to the *CNIH4* gene, cells transfected with *LRRK2* G2019S mutant cDNA resulted in a significant 1.7 fold ($p = 0.001$) increase in splicing in of exon 10 of *MAPT*, but had no effect on the inclusion of exon 5 of the *SNCA* gene (FIG. 2B and C). In contrast, cells which over-expressed wildtype *LRRK2* significantly increased 1.6 fold ($p = 0.005$) inclusion of exon 5 of *SNCA*, but had no effect on the alternative splicing of *MAPT* (FIG. 2B and C).

Dysregulated alternative splicing is a common effect in PD brains

TARDBP and *FUS* genes are two major neurodegenerative genes that code for hnRNPs involved in gene expression and RNA metabolism.¹² Our western blot data suggests that *LRRK2* might act to control subcellular levels of TDP-43 (FIG. 1), and thus may act in part via the same pathogenic pathway on gene expression and RNA metabolism. In order to identify common effects of the *LRRK2* (G2019S), *TARDBP* (M337) and *FUS* (R521H) mutants, we compiled a list of differentially expressed genes (Supplementary Data 1) and spliced exons (Supplementary Data 2) in SK-N-MC cells over-expressing these mutant cDNAs. Thirty-one genes appear to be consistently affected by the over-expression of mutant *LRRK2*, *TARDBP* or *FUS* (FIG. 3A). Biological pathway analysis did not reveal any significant enrichment of pathways from this gene list. Eight genes (*ASPM*, *DPY19L4*, *MPHOSPH10*, *NLGN1*, *PRKAR2B*, *RAB1A*, *SMAD2*, *VANGLI*) were chosen from this list for validation by realtime RT-PCR with an emphasis on genes with neuronal functions (*NLGN1*²⁵, *VANGLI*²⁶) or known interactions with *LRRK2* protein (*RAB1A*²⁷). None of the changes in gene expression were successfully replicated with samples from all three mutant transfection groups.

Of the exons identified as significantly differentially spliced (Supplementary Data 2), 244 exons were common to all three mutant gene lists (FIG. 3A). This represented an enrichment of exons encoded by cytoplasmic proteins ($p = 0.010$).²⁰ Four exons from the list (*DST*, *HSP5*, *PPM1A*, *ZNRD1*) were chosen for validation based on top hits (*HSP5*, *PPM1A* and *ZNRD1*) and a gene involved in neurodegeneration (*DST*).²⁸ Over-expression of all three mutant genes in SK-N-MC cells resulted in increased inclusion of exon 2 of the Hermansky-Pudlak syndrome 5 (*HSP5*) gene (1.7 to 3 fold; $p = 0.024$ to $p = 0.005$) compared to the LacZ control (FIG. 3B and C). A similar effect was seen for the zinc ribbon domain containing 1 (*ZNRD1*) gene, in which increased inclusion of exon 2 was observed for cells over-expressing the FUS(R521H) (1.9 fold; $p = 0.001$) and TARDBP(M337V) (1.6 fold; $p = 0.010$) mutants (FIG. 3B and C) compared to LacZ control.

Several Affymetrix exon probes for Dystonin (*DST*) gene were identified as being significantly affected by over-expression of the three mutant genes (Supplementary Data 2), consistent with the observation that *DST* undergoes complex alternative splicing to generate multiple protein isoforms.²⁹ The probe 2958477 corresponds to the inclusion of exons coding for the *DST* 1e precursor (RefSeq NM_001723). Over-expression of all three mutants, but not wildtype LRRK2, decreased the inclusion of the *DST* 1e precursor specific exons compared with lacZ control, with significance reached for LRRK2(G2019S) (log2 2 fold; $p = 0.001$) and FUS(R521H) (log2 1.3 fold; $p = 0.005$) mutants (FIG. 3D).

We proceeded to determine whether the aberrant splicing of *DST*, *MAPT* and *SNCA* in our cellular model was also observed in post-mortem brain tissue of neuropathologically defined PD cases (Supplementary materials and methods, FIG. 4). We demonstrated that alternative splicing of *SNCA* was significantly altered in PD cases, with a 1.9 fold ($p < 0.001$) decrease in inclusion of exon 5 of the *SNCA* gene, compared with neurologically normal brains (FIG. 4A). There was also a significant log2 2.3 fold ($p = 0.005$) decrease in inclusion of the *DST* 1e precursor specific exons in

PD compared with neurologically normal brains (FIG. 4B). No significant changes in alternative splicing of *MAPT* were observed in brain tissue (FIG. 4A). Sex, age and post mortem delay were not significant predictors of alternative splicing in *MAPT*, *SNCA* or *DST* (data not shown, $p > 0.05$).

DISCUSSION

The *LRRK2* gene has emerged as one of the most prevalent genetic causes of PD.⁷ This is the first study to demonstrate that the *LRRK2* gene may have a role in alternative splicing of at least two major PD genes, *MAPT* and *SNCA*. Dysfunction in the alternative splicing of *MAPT* has been shown in genetic forms of frontotemporal dementia to alter the relative ratios of key splice isoforms crucial for axonal integrity.³⁰ Similarly, a splice isoform of the *SNCA* gene lacking exon 5 (Δ exon5) had been shown to inhibit proteasomal function and preferentially form aggregates *in vitro*.³¹ In our cell systems we demonstrate that the over-expression of mutant *LRRK2* caused a similar change in *MAPT* splicing to frontotemporal dementia. The lack of aberrant splicing of the *MAPT* gene in our brain cohort (FIG. 4A) was expected (the cases did not have frontotemporal dementia) and suggests that the gene association between PD and *MAPT* is due more to gene expression³² than alternative splicing. Our cell systems also revealed that overexpression of wildtype *LRRK2* increased the alternatively spliced, aggregate-forming *SNCA* Δ exon5 isoform, providing a mechanism linking *LRRK2* to α -synuclein neuropathology. The significant increase in the *SNCA* Δ exon5 isoform in our PD brain tissue (FIG. 4A) is consistent with this mechanism and confirms previous studies.³¹

Proteins that interact with the basal splicing protein complex¹¹ affect alternative splicing of genes and are regulated by growth factor-dependent kinase phosphorylation.¹⁹ Such proteins include the hnRNPs FUS and TDP-43. Subcellular fractionation of cells over-expressing *LRRK2* demonstrated that the *LRRK2* protein was predominantly found in cytoplasmic and lipid raft fractions (FIG. 1C), indicating that *LRRK2* does not act directly on the basal splicing protein complex, but may act indirectly by phosphorylating hnRNPs.

Dystonin belongs to the Plakins family of proteins, which function to link cellular cytoskeletal elements with each other and connect them to junctional complexes.²⁸ Our exon-array data suggest that altered splicing of the *DST* locus represents a common mechanism by which mutations in *TARDBP*, *FUS* and *LRRK2* genes (FIG. 3A and D) may give rise to neurodegeneration (FIG. 3A and D). Consistent with this observation was that TDP-43 was shown to bind directly to *DST* transcripts and depletion of the TDP-43 molecule resulted in increased splicing out of a *DST* exon.³³ We also demonstrate that there was a significant decrease in inclusion of the exon encoding the *DST* 1e precursor splice isoform in PD brain tissue. It still remains to be elucidated the exact biological role of the 1e precursor isoform and how alterations in the levels of this splice isoform may contribute to PD. The main limitation of this study is the use of over-expression of the wildtype and mutant proteins in transfected neuroblastoma cells as an experimental model, which does not represent the normal level of *LRRK2* expression in the brain. Thus, conclusive evidence regarding the effect of *LRRK2* on alternative splicing, and more importantly whether the G2019S mutation represents a further gain-of function in terms of its ability to affect alternative splicing of key neurodegenerative genes (FIG. 2A), will come from analyses of brain tissue of *LRRK2* G2019S mutation carriers. Of further interest is whether the effect on alternative splicing is specific to the G2019S mutation as mutations have been shown to alter the function of various domains of the *LRRK2* protein and are associated with different clinical symptoms and neuropathologies.⁹ Finally, while we have demonstrated that cellular *LRRK2* overexpression changes the isoform expression of *MAPT*, *SNCA* and *DST* genes, only the latter two genes were observed to have altered splicing in post-mortem PD brains. This suggests to us the importance of aberrant RNA metabolism as a common pathogenic pathway in idiopathic PD that may in part be regulated by *LRRK2* dysfunction.

Acknowledgements

We thank Dr M Crowley (Peter Wills Bioinformatics Centre, Sydney Australia) for his analysis of the exon array data. We thank Dr IP Blair (ANZAC Institute, Sydney Australia) for the gift of the mutant TARDBP and FUS mutant cDNAs, and Prof WP Gai (Flinders University, Adelaide Australia) for the gift of the wildtype and mutant LRRK2 cDNAs. Brain tissue was received from the Sydney Brain Bank at Neuroscience Research Australia, which is supported by Neuroscience Research Australia, University of New South Wales and National Health and Medical Research Council of Australia (NHMRC); and the New South Wales Tissue Resource Centre at the University of Sydney which is supported by NHMRC, Schizophrenia Research Institute and National Institute of Alcohol Abuse and Alcoholism (NIH (NIAAA) R24AA012725). This study was funded by the NHMRC (Project Grant 510218 to JBJK; Fellowship 630434 to GMH). DE was supported by a Viertel Post-Doctoral Fellowship awarded by Alzheimer's Australia Research.

Authors' contributions

JBJK conceived this entire study, with GMH organising the human tissue study (tissue collection and diagnosis, ethics and tissue request). GMH is CI on the research programs that longitudinally follow brain donors with Parkinson's disease and she is also director of the Sydney Brain Bank. DE, SK, and SG performed experiments. JBJK, DE and SK participated in the management, analysis, interpretation of data and drafting of manuscript. All authors have critically revised the manuscript for important intellectual content and have seen and approved the final version.

Full Financial Disclosures of all Authors for the Past Year

1) John BJ Kwok

Stock Ownership in medically-related fields - None	Intellectual Property Rights – None
Consultancies - None	Expert Testimony - None
Advisory Boards - None	Employment – Salary paid by NHMRC Grant 510217

Partnerships - None	Contracts - None
Honoraria - None	Royalties - None
Grants –NHMRC Grant APP1005769 (awarded Year 2010)	Other - None

2) David Elliott

Stock Ownership in medically-related fields - None	Intellectual Property Rights – None
Consultancies - None	Expert Testimony - None
Advisory Boards - None	Employment – I have been employed in 2 locations during the preceding 12 months, thus I have had 2 sources of salary: 1) A Fellowship from Alzheimer’s Australia Research. 2) The German Centre for Neurodegenerative Disease.
Partnerships - None	Contracts - None
Honoraria - None	Royalties - None
Grants –NHMRC Grant APP1005769 (awarded Year 2010)	Other - None

3) Woojin S Kim

Stock Ownership in medically-related fields - None	Intellectual Property Rights – None
Consultancies - None	Expert Testimony - None
Advisory Boards - None	Employment – Salary paid by NHMRC Grant 510217
Partnerships - None	Contracts - None
Honoraria - None	Royalties - None
Grants –NHMRC Grant APP1005769 (awarded Year 2010)	Other - None

4) Sarsha Gorrissen

Stock Ownership in medically-related fields - None	Intellectual Property Rights – None
--	-------------------------------------

Consultancies - None	Expert Testimony - None
Advisory Boards - None	Employment – Salary paid by NHMRC Grant 510217
Partnerships - None	Contracts - None
Honoraria - None	Royalties - None
Grants – None	Other - None

5) Glenda Halliday

Stock Ownership in medically-related fields – Cochlear (2004 on) & NIB Holdings (2007 on)	Intellectual Property Rights – None
Consultancies - for committee work for the NHMRC	Expert Testimony - None
Advisory Boards - None	Employment – Salary from NHMRC Grant 630434 & University of New South Wales
Partnerships - None	Contracts - None
Honoraria - for travel for conference participation from a number of professional societies, and speaker fees from Elan Pharmaceuticals San Francisco & Novartis Japan	Royalties - Elsevier (for book sales from 1990 and 2006)
Grants – NHMRC project grants (1008307, 570850, 401162), Parkinson's NSW Unity walk research grant (2011), University of New South Wales research grants (2011 Goldstar award, 2011 Intrastructure)	Other - None

References

1. Bertram L and Tanzi RE: The genetic epidemiology of neurodegenerative disease. *J Clin Invest* 2005; 115: 1449-1457.
2. Arima K, Uéda K, Sunohara N et al.: Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. *Brain Res* 1998; 808: 93-100.
3. Marín I, van Egmond WN, van Haastert PJ. The Roco protein family: a functional perspective. *FASEB J* 2008; 22: 3103-3110.
4. Dihanich S, Manzoni C. LRRK2: a problem lurking in vesicle trafficking? *J Neurosci* 2011 ;31: 9787-9788.
5. Hatano T, Kubo S, Imai S et al. Leucine-rich repeat kinase 2 associates with lipid rafts. *Hum Mol Genet* 2007; 16: 678-690.
6. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. *Nature* 2010; 466:637-641.
7. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat Rev Neurosci* 2010;11: 791-797.
8. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord* 2010; 16: 237-242.
9. Wider C, Dickson DW, Wszolek ZK. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. *Neurodegener Dis* 2010; 7: 175-179.
10. Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? *Trends Cell Biol* 2011; 2: 257-265.
11. Black DL. Mechanisms of alternative pre-messenger RNA splicing. *Annu Rev Biochem* 2003; 72: 291-336.
12. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging

- roles in RNA processing and neurodegeneration. *Hum Mol Genet* 2010; 19 (R1) :R46-64.
13. Maracchioni A, Totaro A, Angelini DF et al. Mitochondrial damage modulates alternative splicing in neuronal cells: implications for neurodegeneration. *J Neurochem.* 2007;100: 142-153.
 14. Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. *Biochem Biophys Res Commun.* 2009;387: 149-152.
 15. Sreedharan J, Blair IP, Tripathi VB et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 2008; 319:1668-1672.
 16. Vance C, Rogelj B, Hortobágyi T et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* 2009; 323:1208-1211.
 17. Luty AA, Kwok JB, Dobson-Stone C et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. *Ann Neurol* 2010; 68:639-649.
 18. Adam RM, Yang W, Di Vizio D, Mukhopadhyay NK, Steen H. Rapid preparation of nuclei-depleted detergent-resistant membrane fractions suitable for proteomics analysis. *BMC Cell Biol* 2008; 9: 30.
 19. Benjamini Y, Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Roy Statist Soc Ser B* 1995; 57: 289–300.
 20. Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. *Nucleic Acids Res.* 2011; 39 (Web Server issue):W323-327.
 21. Urwin H, Ghazi-Noori S, Collinge J, Isaacs A. The role of CHMP2B in frontotemporal dementia. *Biochem Soc Trans* 2009; 37: 208-212.
 22. Perron MP, Provost P. Protein components of the microRNA pathway and human diseases. *Methods Mol Biol* 2009; 487 :369-385.

23. Liu B, Liu Y, Chen J, Wei Z, Yu H, Zhen Y, Lu L, Hui R. CARP is a novel caspase recruitment domain containing pro-apoptotic protein. *Biochem Biophys Res Commun* 2002; 293:1396-1404.
24. Edwards TL, Scott WK, Almonte C et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. *Ann Hum Genet* 2010; 74: 97-109.
25. Lee H, Dean C, Isacoff E. Alternative splicing of neuroligin regulates the rate of presynaptic differentiation. *J Neurosci* 2010; 30:11435-11446.
26. Iliescu A, Gravel M, Horth C, Kibar Z, Gros P. Loss of membrane targeting of Vangl proteins causes neural tube defects. *Biochemistry* 2011; 50: 795-804.
27. Kicka S, Shen Z, Annesley SJ, Fisher PR, Lee S, Briggs S, Firtel RA. The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton. *Mol Biol Cell* 2011; 22:2198-2211.
28. Sonnenberg A, Liem RK. Plakins in development and disease. *Exp Cell Res* 2007; 313: 2189-2203.
29. Leung CL, Zheng M, Prater SM, Liem RK. The BPAG1 locus: Alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. *J Cell Biol* 2001; 154: 691-697.
30. D'Souza I, Schellenberg GD. Regulation of tau isoform expression and dementia. *Biochim Biophys Acta* 2005; 1739: 104-115.
31. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. *Acta Neuropathol* 2006; 112: 237-251.
32. Kwok JB, Teber ET, Loy C et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. *Ann Neurol* 2004; 55: 329-334.
33. Polymenidou M, Lagier-Tourenne C, Hutt KR et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci*

2011; 14:459-468.

Table 1: Validation by realtime RT-PCR of candidate genes associated with *LRRK2* over-expression

Gene	Biological Process #	<i>LRRK2</i> (wt)		<i>LRRK2</i> (G2019S)	
		Log 2 Fold change (Microarray p value)	Log 2 Fold change (RT- PCR corrected p value)	Log 2 Fold change (Microarray p value)	Log 2 Fold change (RT- PCR corrected p value)
<i>CHORDC1</i>	chaperone-mediated protein folding	2.2 (0.006)*	1.6 (0.529)	1.4 (0.218)	3.9 (0.220)
<i>CHMP2B</i>	cellular membrane organization	1.4 (0.023)*	2.7 (0.335)	1.2 (0.251)	2.5 (0.465)
<i>TARDBP</i>	Transcription regulation, mRNA processing	1.3 (0.014)*	2.9 (0.040)*	1.1 (0.168)	3.0 (0.073)
<i>BRCA1</i>	Cell cycle, DNA repair	1.3 (0.015)*	2.8 (0.080)	1.1 (0.224)	1.2 (0.465)
<i>MAPK8</i>	histone deacetylase regulator activity, regulation of protein localization	1.2 (0.003)*	2.0 (0.324)	1.1 (0.241)	0.5 (0.888)
<i>TMEM100</i>	integral to membrane	1.2 (0.042)*	3.8 (0.005)*	1.0 (0.792)	2.9 (0.073)
<i>DICER</i>	RNA-mediated gene silencing	1.2 (0.006)*	3.2 (0.005)*	1.1 (0.047)*	2.2 (0.073)
<i>NDUFA4</i>	mitochondrial electron transport, NADH to ubiquinone	1.2 (0.115)	2.6 (0.064)	- (0.038)*	1.4 2.1 (0.090)
<i>CD1C</i>	antigen processing and presentation	- 1.1 (0.115)	0.4 (0.675)	1.1 (0.048)*	0.2 (0.888)

terms derived from gene ontology databases.²⁰* significance at $p < 0.05$.

Figure Legends

FIG. 1: Modulation of *LRRK2* expression by transfection of expression constructs with the full-length wildtype or G2019S mutant *LRRK2* cDNA led to altered TDP-43 levels. A) Western blot analysis shows endogenous TDP-43 levels in the cytoplasmic (cyto-) and nuclear (nuc-) fractions of transfected cells over-expressing *LRRK2* compared with LacZ. The house keeping β -actin protein was used to normalise protein levels. B) Chemiluminescent band intensities were quantified and the levels of cytoplasmic (grey columns) and nuclear (black columns) TDP-43 proteins are presented relative to the LacZ control transfection. Mean and standard error of mean from 5 transfections. Significance of $p < 0.05$ is indicated (*). C) Western blot analysis of lipids from raft and non-raft fractions show that both the wildtype and G2019S *LRRK2* protein did not differ markedly in their distribution between raft and non-raft fractions. $\text{Go}\alpha\text{-2}$ (raft specific) and calnexin (non-raft specific) were used to normalise protein levels.

FIG. 2: Comparison between the effects of wildtype and G2019S mutant *LRRK2* over-expression on gene expression and alternative splicing in transfected cells. A) Venn diagrams indicate marked overlap in the list of genes whose expressions were differentially regulated by the wildtype and mutant *LRRK2*. Little overlap was observed in the list of genes whose exons are differentially spliced in cells over-expressing the two *LRRK* cDNAs. B) Agarose gel electrophoresis of RT-PCR products showing differential alternative splicing of endogeneous *CNIH4*, *MAPT* and *SNCA* transcripts isolated from transfected cells. C) Quantification of ethidium bromide stained RT-PCR bands for cells transfected with LacZ (white columns), *LRRK2*(wildtype) (grey columns) and *LRRK2*(G2019S) (black columns) cDNAs. Mean and standard error of mean from 5 transfections. Significance of corrected $p < 0.05$ (*) is indicated.

FIG. 3: Comparison between the mutant forms of three neurodegenerative genes on gene expression and alternative splicing in transfected cells. A) Venn diagrams indicate marked overlap in genes whose expressions were differentially regulated by the mutant *LRRK2*, *TARDBP* and *FUS*. B) Agarose gel electrophoresis of RT-PCR products showing differential alternative splicing of endogenous *HSP5* and *ZNRD1* transcripts isolated from transfected cells. C) Quantification of ethidium stained RT-PCR bands for cells transfected with LacZ (white columns), LRRK2(G2019S) (black columns), FUS(R521H) (light grey columns) and TARDBP(M337V) (dark grey columns) cDNAs. D) Quantification of *DST* alternatively spliced exon by quantitative realtime RT-PCR. Mean and standard error of mean from n = 5 transfections. Significance of corrected $p < 0.05$ (*) is indicated.

FIG. 4: Examination of alternative splicing in affected brain samples from patients with Parkinson's disease compared with neurologically normal controls. A) Quantification of ethidium stained bands for *MAPT* (grey columns) and *SNCA* (black columns) RT-PCR products B) Quantification of *DST* alternatively spliced exon by quantitative realtime RT-PCR. Mean and standard error of mean from n = 10 PD and n = 8 control samples. Significance of corrected $p < 0.05$ (*) and $p < 0.001$ (**) are indicated.